LALPATHLAB2023-10-012023-12-31 LALPATHLAB2023-10-012023-12-31 LALPATHLAB2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member LALPATHLAB2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member LALPATHLAB2023-12-31 LALPATHLAB2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LALPATHLAB2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539524 LALPATHLAB NOTLISTED Dr. Lal Path Labs Ltd. Equity 2023-04-01 2024-03-31 2024-02-01 2024-01-25 INR Millions Third quarter 11:30:00 13:20:00 2024-02-01 2024-02-01 Not applicable Single segment The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2023-10-01 2023-12-31 Unaudited Consolidated 5389000000.00 183000000.00 5572000000.00 1070000000.00 0.00 0.00 1090000000.00 70000000.00 360000000.00 1823000000.00 4413000000.00 1159000000.00 0.00 1159000000.00 344000000.00 -7000000.00 337000000.00 0.00 822000000.00 0.00 0.00 0.00 0.00 822000000.00 2000000.00 824000000.00 813000000.00 9000000.00 815000000.00 9000000.00 835000000.00 10 9.77 9.76 0.00 0.00 9.77 9.76 i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 1 February, 2024. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended December 31, 2023 and they have expressed an unmodified conclusion on the aforesaid results. ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 Interim Financial Reporting ( Ind AS 34 ), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. iv. During the quarter and nine months ended 31 December 2023, the Parent Company has issued 8,000 and 60,000 equity shares of face value of Rs. 10 each respectively, on exercise of employee stock options. Further, during the nine months ended 31 December 2023, the Parent Company has issued 49,975 equity shares of face value of Rs. 10 each, to Dr. Lal Pathlabs Employee Welfare Trust under Employee Stock Option Plan, 2022 ( ESOP Plan, 2022 ). v. The Board of Directors of the Parent Company have approved second interim dividend of INR 12 per equity share (face value of INR 10 each) at their meeting held on 1 February, 2024. The Board of Directors of the Parent Company had approved first interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 27 July, 2023 and this was paid on 23 August, 2023. The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2023. The same was approved by the shareholders in the Annual General Meeting held on 12 September, 2023 and this was paid on 15 September, 2023. Due to size constraint, we have not pasted complete note to statement of financial results. Please refer pdf file for complete notes to the statement of Financial Results for the quarter and nine months ended December 31, 2023. Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 16812000000.00 508000000.00 17320000000.00 3425000000.00 0.00 0.00 3191000000.00 228000000.00 1070000000.00 5550000000.00 13464000000.00 3856000000.00 0.00 3856000000.00 1154000000.00 -63000000.00 1091000000.00 0.00 2765000000.00 0.00 0.00 0.00 0.00 2765000000.00 3000000.00 2768000000.00 2732000000.00 33000000.00 2735000000.00 33000000.00 835000000.00 10 32.88 32.81 0.00 0.00 32.88 32.81 Fees to collection centers/channel partners 777000000.00 Other expenses 1046000000.00 Fees to collection centers/channel partners 2374000000.00 Other expenses 3176000000.00 Remeasurement of the defined benefit n obligations 4000000.00 Remeasurement of the defined benefit n obligations 8000000.00 4000000.00 8000000.00 1000000.00 2000000.00 Exchange differences on translation of foreign operations -1000000.00 Exchange differences on translation of foreign operations -3000000.00 -1000000.00 -3000000.00 0.00 0.00